Clinical Observations

Similar documents
Deciding what to do about Rheumatoid Arthritis

Measuring Patient Outcomes:

Inflammatory arthritis Shared Decision Making

What is Enbrel? Key features

New Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

Bringing the clinical experience with anakinra to the patient

The Hospital for Sick Children Technology Assessment at SickKids (TASK)

New Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate

Research Article Traditional Chinese Medicine Zheng in the Era of Evidence-Based Medicine: A Literature Analysis

COSENTYX (secukinumab)

Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis

TCM Ideology and Methodology

Tocilizumab (Actemra )

A 3-page standard protocol to evaluate rheumatoid arthritis (SPERA): Efficient capture of essential data for clinical trials and observational studies

Non-commercial use only

Guide to Understanding and Managing Arthritis

Appendix 1: Frequently Asked Questions

Key Words: Rheumatoid Arthritis, etanercept, post-marketing study, comparative study

1.0 Abstract. Title. Keywords. Adalimumab, Rheumatoid Arthritis, Effectiveness, Safety. Rationale and Background

Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Understanding Rheumatoid Arthritis

TOFACITINIB PATIENT INFORMATION ON. (Brand name: Xeljanz ) What is tofacitinib? Important things to remember

NHS Suffolk Shared Care Guidelines for the Treatment of Rheumatoid Arthritis with LEFLUNOMIDE

apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions

Gender differences in effectiveness of treatment in rheumatic diseases

Subject: Remicade (Page 1 of 5)

G. Poór for the Leflunomide Multinational Study Group and V. Strand 1

2.0 Synopsis. Adalimumab DE019 OLE (5-year) Clinical Study Report Amendment 1 R&D/06/095. (For National Authority Use Only)

SCIENTIFIC DISCUSSION. London, 27 April 2006 Product name: HUMIRA/TRUDEXA Procedure number: EMEA/H/C/ /II/26

Development of Classification and Response Criteria for Rheumatic Diseases

Effects of Acupuncture on Chinese Adult Patients with Psoriatic Arthritis: A Prospective Cohort Study

Rheumatoid arthritis 2010: Treatment and monitoring

PDF of Trial CTRI Website URL -

London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8

Introduction AIM OF THE STUDY

CDEC FINAL RECOMMENDATION

The Medical and Manual Osteopathic Treatment of Rheumatoid Arthritis 1. The Medical and Manual Osteopathic Treatment of Rheumatoid Arthritis

A Clinical Context Report

Coverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication

axial spondyloarthritis including ankylosing spondylitis

New Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab

BIOLOGICS AND RISK OF MALIGNANCIES: SCREENING PROCEDURES AND PATIENT FOLLOW UP

Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent

certolizumab pegol (Cimzia )

Your treatment with XELJANZ

Product: Femmerol. Client: Solutions for Women, LLC 315 North Village Avenue New York, (516)

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

JMSCR Vol 05 Issue 09 Page September 2017

Tofacitinib ( Xeljanz) Marshall Porter & Lauren Ysais

How does my new treatment work?

2017 Blue Cross and Blue Shield of Louisiana

Horizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.

Clinical Study Results

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Synopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier

Psoriatic Arthritis- Secondary Care

Review Article Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis

Bridges Family Wellness PC. New Patient Intake. Bridges Family Wellness Intake Form SE Lake Rd, Suite 102 Milwaukie, OR

This is a repository copy of Psoriasis flare with corticosteroid use in psoriatic arthritis.

1.0 Abstract. Title. Keywords. Rationale and Background

Using ENBREL to Treat Rheumatoid and Psoriatic Arthritis

2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1093. (For National Authority Use Only)

Step-by-step instructions for intravenous (iv) infusions for patients with:

Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis

The use of methotrexate in rheumatological conditions A review of the evidence. Maureen Cox January 2009

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:

(minutes for web publishing)

Rituximab (Rituxan )

Treatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

2017 Blue Cross and Blue Shield of Louisiana

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

PFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.

Drug information. Sarilumab SARILUMAB. is used to treat rheumatoid arthritis. Helpline

24 h. P > h. R doi /j. issn

Psoriatic Arthritis- Second Line Treatments

PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.

REDUCE THE HURT REDUCE THE HARM

ORENCIA (abatacept) Demonstrates Comparable Efficacy to Humira ( adalimumab

Abatacept. What is abatacept?

A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis Choi H K, Seeger J D, Kuntz K M

PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

SYNOPSIS. The study results and synopsis are supplied for informational purposes only.

HERNOVIR 200 mg tablets

Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment

SYNOPSIS. Issue Date: 17 Jan 2013

golimumab Principal Investigator(s): Principal Investigator: Michael E. Weinblatt, MD Brigham and Women s

Integrative network analysis: Bridging the gap between Western medicine and traditional Chinese medicine

Erelzi (etanercept) Frequently Asked Questions

For the Patient: ULUAVPMTN

SULFASALAZIN 500mg enteric-coated tablets

SCIENTIFIC DISCUSSION

Sponsor: Sanofi Drug substance(s): GZ316455

LOCALLY AVAILABLE BIOLOGIC AGENTS IN THE TREATMENT OF PSORIATIC ARTHRITIS

New Patient Medical History Intake Form

Transcription:

50 Journal of Traditional Chinese Medicine, March 2011; 31(1): 50-55 Clinical Observations The Extraarticular Symptoms Influence ACR Response in the Treatment of Rheumatoid Arthritis with Biomedicine: A Single-blind, Randomized, Controlled, Multicenter Trial in 194 patients ZHANG Chi 1, ZHA Qing-lin 2, HE Yi-ting 3, JIANG Miao 1, LÜ Cheng 1, And LÜ Ai-ping 1, 4 Objective: The extraarticular symptoms are important in the pattern differentiation of traditional Chinese medicine (TCM), and the present study is designed in an attempt to find the associations between the extraarticular symptoms and American College of Rheumatology (ACR) Response in 194 cases of rheumatoid arthritis (RA) treated with biomedicine. Methods: The data were obtained from a randomized clinical trial. One hundred ninety-four RA patients were treated with the biomedical therapy (diclofenec, methotrexate and sulfasalazine). ACR20 response in 24 weeks was used for the efficacy evaluation. Eighteen symptoms (including 13 extraarticular symptoms) that TCM practitioners focus on were collected for exploration on the association between the symptoms and the efficacy of the biomedical therapy with association rules method. Results: After 24 weeks, a total of 135 patients receiving biomedicine had achieved an ACR20 response. The association rules analysis on each symptom showed that soreness in the waist was more associated with ACR20 response, but with lower support (selected sample size based, 20.10% and 14.95% respectively); cold intolerance and cold joint were found to be associated with ACR20 response with higher support (48.97% and 53.61% respectively), and the confidences (predicted effective rate) were 73.08% and 71.23% respectively. The associations between combination of symptoms (among them, there was at least one extraarticular symptom) and ACR20 response indicated that cold intolerance or cold joint with higher confidence and support were the most important extraarticular symptoms. Conclusion: The RA patients with cold intolerance and cold joints, which are the extraarticular symptoms that TCM practitioners focus on, may show higher ACR20 response when treated with the biomedical approach. Keywords: symptoms; Chinese medicine; rheumatoid arthritis Rheumatoid arthritis (RA) is a long-term disease that causes inflammation of the joints and surrounding tissues, leading to a wide variety of symptoms and signs. 1 The symptoms in RA are diversified, and can be basically classified into the articular and extraarticular ones. The extraarticular symptoms, such as depression, are associated with inflammation and appear to have independent effects on perceived pain in rheumatoid arthritis. 2 While more extraarticular symptoms, such as intolerant to cold and cold joint, are considered to be most important evidence for Traditional Chinese medicine (TCM) pattern differentiation (similar to diagnosis in biomedicine), which guides TCM therapy in the treatment of disease. 3 The authors previous study showed that TCM pattern differentiation based on the symptoms can help identify a subset of rheumatoid arthritis patients that will more likely respond to biomedical therapy, 4 though TCM pattern differentiation is hard to be understood by biomedical scientists. Using statistical tools and modeling techniques, the interesting and hidden rules in the data may be found, and the association rules is one of the important data mining tasks which can reveal the relationships among different items. 5-7 In this paper, the authors applied the standard data mining technique of the association rules as a basis to explore the clinical trial data on RA patient in order to show the influence of extraarticular symptoms on ACR20 response in the treatment with the biomedicine approach. METHODS 1 Study Design This multicenter, randomized, single-blind (patients were unaware of detailed therapy) study, in which the assessors (rheumatologists) blinded, was conducted at 9 1. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China; 2. Jiangxi TCM University, Nanchang, Jiangxi 330006, China; 3. Guangdong Traditional Chinese Medicine Hospital, Guangzhou, Guangdong 510120, China; 4. E-institute of Shanghai Municipal Education Commission, Shanghai TCM University, Shanghai 200032, China Correspondence to: LÜ Ai-ping, Tel.: 86-10-64067611, E-mail: lap64067611@126.com This research is supported by the National Tenth Five Year Plan Project of China, Projects from National Science Foundation of China (No.30825047), National Eleventh Plan Project (No. 2006BAI04A10), and by E-institutes of Shanghai Municipal Education Commission (No. E03008).

Journal of Traditional Chinese Medicine, March 2011; 31(1): 52-55 51 centers in China. The primary endpoint was ACR 20 in 24 weeks. More details about the clinical trial have been reported previously. 8 Inclusion Criteria Men and women, aged from 18 to 70 years, were eligible to participate if they met the American College of Rheumatology (ACR) criteria for RA, with disease duration at least for one year, and the illness condition categorized as Class I, II, or III under ACR guidelines. 9 Patients who agree to sign an informed consent were obtained. Exclusion Criteria The patients with severe cardiovascular, lung, liver, kidney, hematologic or mental disease, and women who were pregnant, breast-feeding or were planning to be pregnant in the following 8 months were excluded. Sample Size Determination The sample size was established by comparing the rates of validity between TCM and Western medicine. In reviewing the literature, the sample size can be calculated by the estimated value of the rate of validity for the formula, 91.11% in the TCM group and 79.00% in Western medicine group (set =0.05, =0.10). Sample size was 201 in both groups. And with a dropout rate for follow up as 20%, the sample size for each group was 241 and 482 in the two groups. Randomization The patients were randomized by computer using the SZS-12 PRCO PLAN system (Version 6.12 for Windows). The details of the allocation sequence were in a sealed envelope and unknown by the study investigators and the participants. Randomization was designed so that each participant would have a 50% chance of assignment to one of the two groups, and each participant had their own unique code number. Only this number was used to identify the patients Case Report Form. Blinding As for the different interventions in the trial, some drugs have adverse reactions (such as the effect of Tripterygii totorum on the reproductive system). Case group division is adapted to single-blind method with the therapeutic effects and side effects evaluated by an independent third party. The study was approved by the Ethical Research Committee, Guangdong Provincial Hospital of Traditional Chinese Medicine. Informed consent was obtained from each patient. Procedures From February 1997 to November 1997, a total of 522 patients were enrolled into the study. Of these 522 patients, 489 qualified for the clinical study and 437 patients complete the follow up. (Flow Chart 1). 522 screened 33 excluded: --21 exclusion criteria --12 refused to participate 489 randomized 247-TCM group 242 -WM group 29 discontinued 13 lack of efficacy 6 adverse events 8 patients withdrew 2 other reasons 23 discontinued 5 lack of efficacy 6 adverse events 9 patients withdrew 3 other reasons 218 completed 24 weeks 219 completed 24 weeks No one included in this analysis 194 included in this analysis (complete data) Flow Chart 1. Number and reasons for patients not completing the study.

52 Journal of Traditional Chinese Medicine, March 2011; 31(1): 50-55 Trial Profile Fifty-seven patients withdrawn from the study, 18 due to poor efficacy, 17 according to their request, 5 for other reasons (change job; attending training classes and starting a new job) and 17 because of adverse effects. None of the adverse effects was serious. Of the 437 patients who completed the follow-up, 41 patients who did not receive laboratory examination were not included in the PPSA and X-ray analysis. One hundred ninety-four patients in WM group with a Disease Activity Scores that include different 28-joint (DAS28-3) score of higher than 2.6 were admitted into statistical analysis. Interventions Patients in Western medicine-treated group: Biomedical combination therapy using both the nonsteroidal antiinflammatory drugs (NSAIDs) and the disease modifying anti-rheumatic drugs (DMARDs). Diclofenec (extended action 75 mg tablet) as the NSAID was orally taken once a day after a meal till the acute inflammation was controlled. The DMARDs used were Methotrexate (MTX) and Sulfasalazine (SSZ). MTX was orally taken once a week at a starting dosage of 5 mg with addition of 2.5 mg each week up to 15 mg, and a maintenance dosage from 2.5 mg to 7.5 mg. SSZ was orally taken twice a day from a starting dosage of 0.25 g with the addition of 0.25 g each week, to a maintenance dosage of 0.5 g to 1 g, four times a day. Measurements In the 12th week and the 24th week, the ACR20 was recorded and used for the evaluation of efficacy. 9 Efficacy evaluation was done by a third party (rheumatologists at each center) who did not know the biomedical combination therapy. Within 14 days before randomization, a complete physical examination, medical history, and assessment of 18 symptoms (joint pain, joint tenderness, joint swelling, joint stiffness, cold intolerance, soreness in the waist, frequent urination at night, hot joint, thirsty, fatigue, dysphoria, cold limbs, vexation, fever, weakness in the waist, dizziness, turbid urine in yellow color, numb heavy limbs) typically evaluated by TCM physicians were performed and recorded. Only patients treated with the biomedical combination therapy were included for analysis in this study. Disease activity was assessed by DAS28-3. Only patients with a DAS28-3 score higher than 2.6 were admitted into statistical analysis. Safety Analyses Five hundreds and ten patients were included in the Safety analyses. Role of the Funding Sources This study was supported by the National Key Project of the 10th Five-Year Plan. The funding sources had no role in study design; collection, analyses, and interpretation of all data; writing the article; and the decision to submit the manuscript for publication. Statistics Sample size for this study was calculated based on an estimate for TCM response rate of 91.11% and WM ACR20 response rate of 79.00% referring to previous clinical literature. The sample size calculation was performed using the formula of proportions under the assumption of a two-tailed test with 80% power and an alpha level of 0.05. The required sample size was therefore 201 cases in each group. The sample size was increased to 241 in each group to allow for withdrawals. 8 Association rules on SAS 9.1 Enterprise Miner statistical package (Order No. 195557) were used. In this study, the symptoms (including some signs such as joint swelling) were set as items. In order to clarify the rules, the definitions for Support and Confidence are described with the following examples: Suppose the {item: symptom A} ==> Effective as association rule, 39 patients with symptom A have effect, 194 patients got biomedical combination therapy, then the Support is 39/194 = 20.10%. Suppose the {item: symptoms A} ==> Effective as association rules, 28 patients (responsive case number) with symptom A have effect, total 47 patients with symptom A, then the Confidence is 28/47 = 82.98%. Suppose the {item: symptoms A & symptoms B} ==> Effective as association rules, which means that the patients with both symptom A and symptoms B have effect, the Confidence and Support will be as described above. A Chi-Square test is conducted to determine whether the baseline data (gender, age) for RA patients with the symptoms related to 11 association rule are statistically different from what was expected as compared to RA patients without the symptoms related to 11 association rule, which determines whether the implementation (explore the patients with some symptom or symptoms combination) was successful due to process improvements or to chance. Then, the therapeutic efficacy in 194 RA patients with or without the symptoms related to 11 association rules were compared with Chi Square analysis. A Chi-Square test is conducted to determine whether efficiency for the sample group (with the symptoms related to association rule, rule = 0) are statistically different from what was expected as compared to the group (without the symptoms related to association rule, rule = 1). The goal is to have a P-value that is less than 0.05, which means that there is a less than 5% probability for the results that

Journal of Traditional Chinese Medicine, March 2011; 31(1): 52-55 53 could have been produced by chance. RESULTS ACR Efficacy Evaluation Of the 522 patients who underwent randomization, 21 patients were excluded as not meeting the inclusion criteria, and 12 patients were excluded by refusing to participate. 489 were included in the trial, 247 in TCM group, and 242 in biomedical combination therapy group. Baseline characteristics were similar between the treatment groups. 8 Thirty-eight patients in the biomedical combination therapy group dropped out, and a total of 194 patients received for 24 weeks. All the 194 patients treated with the biomedical combination therapy were analyzed. ACR20 response in the 12th week was 36.08%, and ACR20 response in the 24th week was 69.59% (Figure 1). Figure 1. ACR response in RA patients treated with the biomedical combination therapy for 12 weeks and 24 weeks. Association between ACR20 Response and the Extraarticular Symptoms The associations between ACR20 response and single extraarticular symptom were analyzed (rule 1 in Table 1), and the associations between ACR20 response and 2 or 3 combination (of 2 or 3 symptoms) at least including one extraarticular symptom) were analyzed (rule 2 to 11 in Table 1). The first 1 association rule in Table 1 indicated that, with more than 80% confidence, soreness in the waist was more associated with effectiveness. However, the RA patients did not often show single soreness in waist (with support of 20.10%). Cold intolerance and cold joint were found to be associated with ACR20 response with higher support (48.97% and 53.61% respectively), and the confidences were 73.08% and 71.23% respectively. Thus the associations of two or three symptoms with ACR20 response were further explored. From the rule 2 on in Table 1, all rules indicated that cold intolerance or cold joint were the most important extraarticular symptoms, and the ACR 20 response in the cases with diagnostic related articular symptoms combined with these two extra- articular symptoms would be higher than 69.59% (ACR20 response in all 194 patients). The baseline characteristics (gender, age) showed no significant differences between patients with and without one association rule. The of Chi-Square tests represented the therapeutic efficacy in 194 RA patients all showed significant differences between patients with or without symptoms related to 11 association rules (Table 2). Table 1. Association rules obtained from the symptoms of RA and ACR response with biomedical combination therapy No. Association rule Support (%) Confidence (%) Responsive case number 1 {Soreness in waist}==> Effective 20.10 82.98 39 2 {Cold intolerance, Joint stiffness & Joint pain}==> Effective 20.62 93.02 40 3 {Cold intolerance, Joint stiffness & Cold joints} ==> Effective 20.10 90.70 39 4 {Cold intolerance & Joint stiffness} ==> Effective 21.65 87.50 42 5 {Cold intolerance & Joint swelling} ==> Effective 20.62 86.96 40 6 {Cold intolerance, Joint tenderness & Joint pain} ==> Effective 27.32 82.81 53 7 {Cold intolerance & Joint pain} ==> Effective 32.99 82.05 64 8 {Cold intolerance, Joint pain & Cold joints} ==> Effective 30.41 81.94 59 9 {old intolerance & Joint tenderness} ==> Effective 30.93 78.95 60 10 {Cold intolerance, Joint tenderness & Cold joints} ==> Effective 28.35 78.57 55 11 {Cold intolerance & Cold joints} ==> Effective 45.36 75.21 88 Notes: {A} ==> B means that A is more likely associated with B. The Support is the percentage of responsive cases with the symptom in the total treated cases. The Confidence is the percentage of responsive cases with the symptom in the total cases with the symptom. The ACR20 response after treatment with biomedicine for 24 weeks was 69.59% (in total 194 cases) and the rules with Confidence >70% were included.

54 Journal of Traditional Chinese Medicine, March 2011; 31(1): 50-55 Table 2. Therapeutic efficacy in 194 RA patients with or without symptoms related to the 11 association rules No. Association rule Symptom Total Effective (%) P value 1 {Soreness in waist} ==> Effective 0 147 65.31 0.0219 * 1 47 82.98 2 {Cold intolerance, Joint stiffness & Joint pain} ==> Effective 0 151 62.91 0.0002 * 3 {Cold intolerance, Joint stiffness & Cold joints} ==> Effective 4 {Cold intolerance & Joint stiffness} ==> Effective 5 {Cold intolerance & Joint swelling} ==> Effective 6 {Cold intolerance, Joint tenderness & Joint pain} ==> Effective 7 {Cold intolerance & Joint pain} ==> Effective 8 {Cold intolerance, Joint pain & Cold joints} ==> Effective 9 {Cold intolerance & Joint tenderness} ==> Effective 10 {Cold intolerance, Joint tenderness & Cold joints} ==> Effective 11 {Cold intolerance & Cold joints} ==> Effective 1 43 93.02 0 151 63.58 1 43 90.70 0 146 63.70 1 48 87.50 0 148 64.19 1 46 86.96 0 130 63.08 1 64 82.81 0 116 61.21 1 78 82.05 0 122 62.30 1 72 81.94 0 118 63.56 1 76 78.95 0 124 64.52 1 70 78.57 0 77 61.04 1 117 75.21 Notes: Symptom 0=patients with this symptom or symptom combination; Symptom 1= patients without this symptom or symptom combination. * P<0.05 0.0006 * 0.0019 * 0.0034 * 0.0050 * 0.0020 * 0.0041 * 0.0230 * 0.0410 * 0.0358 * DISCUSSION The previous study showed that biomedicine therapy was better in treating RA with TCM cold pattern. 8 However, it is really hard for biomedical scientists to understand the meanings of TCM pattern classification, even harder to understand all the TCM focused extraarticular symptoms. Therefore, it would be important to find out the influence of the common TCM focused extraarticular symptoms on the efficacy in the treatment of RA, with the indication and specification for the biomedicine therapy. In the present study, two extraarticular symptoms, that is cold intolerance and cold joint, were found to be related to ACR20 response for the biomedical combination therapy. Data mining is a technique for discovering the useful information from large databases. A large database represents a huge amount of information which can be potentially very useful if extracted and summarized correctly, and using the statistical tools and modeling techniques, one can discover the interesting and hidden patterns in the data. 5,6 Here, the authors applied the standard data mining technique of association rules as a basis to explore the patients data. Association rule mining is one of the important data mining tasks which may reveal the relationships among different items. 7 Association rule mining technology is being currently used by a number of medical fields, including gene, clinical, and so on. 10,11 Thus, the authors think it would be suitable to apply this approach to explore the influence of the symptoms TCM concerned and ACR20 response. In this paper, the writers used the analysis to explore each of the symptoms and the symptom combinations, and found that cold intolerance and cold joint were the most important symptoms associated with the efficacy. But how to set proper minimum confidence to association rule mining algorithm is a very important issue in applying association rule mining. The association rules are considered interesting if they satisfy both a minimum support threshold and a minimum confidence threshold. Such thresholds can be set by users or domain experts but not a common criterion. There is no general rule to set a proper minimum threshold and the only thing the authors can do is setting minimum threshold by their experience and by characteristic of database. The professional experience includes the relationship between the symptoms and diseases based on TCM theory. Furthermore, all the 194 patients treated with the biomedicine were analyzed, and the ACR20 response in the 24th week was 69.59% (Figure 1). The

Journal of Traditional Chinese Medicine, March 2011; 31(1): 52-55 55 authors use data mining in order to explore patient with some combination of symptoms will get higher response. If the writers set higher threshold, they may get too less association rules, so they set minimum confidence as 70% and get 11 rules. The authors considered that these 11 rules could be used for the further discussion but not too much. In this study, the hypothesis is that, given association rules that capture the characteristics of patients. Then, the authors test the therapeutic efficacy in 194 patients whether have significant differences between patients with or without symptoms related to the 11 association rules that they have captured. That means the therapeutic efficacy in patients with different characteristics is different. And the authors will verify their hypothesis by carrying out next clinical trials and other methods. It has been proved that one of the important symptoms for TCM pattern differentiation could influence the efficacy of therapies, 2 and that some extraarticular or manifestations, such as inflammatory responses in other organs, may lead RA into different progressive way that need different therapeutic approaches. 12 In TCM, all the symptoms and signs (including tongue appearance and pulse feeling, which will not be discussed here because of their complexity in understanding from the view of biomedicine), especially those extraarticular symptoms which exist widely in RA patients but not emphasized by biomedicine, are the important information for TCM pattern differentiation. The previous results showed that RA patients with some specific extra-articular symptom or symptom combination could be treated in more efficient way with a therapeutic method of either biomedicine or TCM. 3 And the results supported that the efficacy of biomedical combination therapy would be better if only used in the RA patients with cold intolerance and cold joint. Few of the rheumatologists care about the extraarticular symptoms in clinical practice in biomedicine, but the TCM doctor does care about it. The writers findings indicate that some extraarticular symptoms should be taken into consideration for the indication and specification of a therapy or an anti-rheumatic drug. The RA patients with intolerance to cold and cold joints, which are the extraarticular symptoms focused by TCM, may show higher ACR20 response when treated with the biomedical approach. The results further suggested that the extraarticular symptoms that TCM practitioners focus on would be useful for specifying the indication of the biomedicine therapy. REFERENCES 1. American College of Rheumatology. Guidelines for the Management of Rheumatoid Arthritis. Arthritis Rheum 2002; 46: 328-346. 2. Kojima M, Kojima T, Suzuki S, Oguchi T, Oba M, Tsuchiya H, et al. Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum 2009, 61: 1018-1024. 3. Zha QL, He YT, Yan XP, Su L, Song YJ, Zeng SP, et al. Predictive role of diagnostic information in treatment efficacy of rheumatoid arthritis based on neural network model analysis. Zhong Xi Yi Jie He Xue Bao 2007; 5: 32-38. 4. Lu C, Zha Q, Chang A, He Y, Lu A. Pattern differentiation in Traditional Chinese Medicine can help define specific indications for biomedical therapy in the treatment of rheumatoid arthritis. J Alt Complement Med 2009; 15: 1021-1025. 5. Brossette SE, Sprague AP, Hardin JM, Waites KB, Jones WT, Moser SA. Association rules and data mining in hospital infection control and public health surveillance. J Am Med Informatics Assoc 1998; 5: 373-381. 6. Serban G, Czibula I, Ampan A. A Programming interface for medical diagnosis prediction. Studia Univ Babes-Bolyai Informatica 2006; Li: 21-30. 7. Agrawal R, Imielinski T, Swami A. Mining association rules between sets of items in large databases. Washington DC: ACM SIGMOD Conference; 1993: 207-216. 8. He Y, Lu A, Zha Y, Yan X, Song Y, Zeng S, et al. Correlations between symptoms as assessed in traditional Chinese medicine (TCM) and ACR20 efficacy response. A study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine. J Clin Rheumatol 2007; 13: 317-321. 9. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheumatism 1995; 38: 727-735. 10. Delgado M, Sanchez D, Mart n-bautista MJ. Mining association rules with improved semantics in medical databases. Artificial Intelligence in Med 2001; 21: 241-245. 11. Creighton C, Hanash S. Mining gene expression databases for association rules. Bioformatics 2003; 19: 79-86. 12. Turesson C, McClelland RL, Christianson T, Matteson E. Clustering of extraarticular manifestations in patients with rheumatoid arthritis. J Rheumatol 2008; 35:179-180. (Received August 06 2010)